Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 7 | 2025 | 413 | 1.480 |
Why?
|
| HIV Infections | 9 | 2023 | 2047 | 1.420 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2023 | 229 | 1.260 |
Why?
|
| Tuberculosis | 5 | 2025 | 556 | 1.040 |
Why?
|
| Neonatology | 1 | 2023 | 57 | 0.780 |
Why?
|
| Mycobacterium bovis | 1 | 2022 | 32 | 0.780 |
Why?
|
| Antiprotozoal Agents | 1 | 2022 | 41 | 0.770 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2022 | 49 | 0.770 |
Why?
|
| Leishmania | 1 | 2022 | 35 | 0.770 |
Why?
|
| Leishmaniasis | 1 | 2022 | 40 | 0.760 |
Why?
|
| Apnea | 1 | 2021 | 31 | 0.720 |
Why?
|
| Cyanosis | 1 | 2021 | 43 | 0.710 |
Why?
|
| Eosinophilia | 1 | 2022 | 106 | 0.700 |
Why?
|
| Maternal Health | 1 | 2020 | 26 | 0.670 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2020 | 27 | 0.660 |
Why?
|
| Fellowships and Scholarships | 1 | 2023 | 325 | 0.650 |
Why?
|
| Hypersensitivity | 1 | 2022 | 196 | 0.650 |
Why?
|
| Malaria | 1 | 2020 | 99 | 0.640 |
Why?
|
| Hookworm Infections | 1 | 2020 | 123 | 0.620 |
Why?
|
| Coinfection | 2 | 2020 | 188 | 0.620 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2019 | 253 | 0.600 |
Why?
|
| Drug Prescriptions | 1 | 2021 | 238 | 0.600 |
Why?
|
| Ambulatory Care Facilities | 1 | 2021 | 242 | 0.580 |
Why?
|
| Education, Medical, Graduate | 1 | 2023 | 564 | 0.580 |
Why?
|
| Family | 1 | 2021 | 595 | 0.540 |
Why?
|
| Community Health Workers | 1 | 2017 | 75 | 0.520 |
Why?
|
| Community Health Services | 1 | 2017 | 92 | 0.520 |
Why?
|
| Education, Distance | 1 | 2017 | 68 | 0.520 |
Why?
|
| Anemia | 1 | 2020 | 350 | 0.510 |
Why?
|
| Parents | 1 | 2023 | 1079 | 0.490 |
Why?
|
| Program Evaluation | 1 | 2017 | 453 | 0.480 |
Why?
|
| Health Personnel | 1 | 2019 | 543 | 0.440 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2025 | 541 | 0.420 |
Why?
|
| Telemedicine | 1 | 2017 | 495 | 0.350 |
Why?
|
| Feces | 2 | 2025 | 753 | 0.340 |
Why?
|
| Social Stigma | 2 | 2021 | 85 | 0.320 |
Why?
|
| Sputum | 3 | 2025 | 116 | 0.310 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2554 | 0.300 |
Why?
|
| Child | 11 | 2025 | 25763 | 0.300 |
Why?
|
| Sensitivity and Specificity | 5 | 2025 | 2139 | 0.280 |
Why?
|
| Humans | 21 | 2025 | 132064 | 0.270 |
Why?
|
| BCG Vaccine | 2 | 2023 | 112 | 0.230 |
Why?
|
| DNA, Bacterial | 2 | 2024 | 494 | 0.220 |
Why?
|
| Adolescent | 8 | 2025 | 20542 | 0.210 |
Why?
|
| Young Adult | 4 | 2024 | 9952 | 0.210 |
Why?
|
| Tuberculosis, Lymph Node | 1 | 2022 | 20 | 0.190 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2022 | 34 | 0.190 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2022 | 28 | 0.190 |
Why?
|
| Surveys and Questionnaires | 2 | 2023 | 3993 | 0.190 |
Why?
|
| Leukocyte Count | 1 | 2022 | 249 | 0.190 |
Why?
|
| Eosinophils | 1 | 2022 | 122 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2021 | 111 | 0.170 |
Why?
|
| Infant, Newborn | 3 | 2023 | 8542 | 0.170 |
Why?
|
| Contact Tracing | 1 | 2021 | 56 | 0.170 |
Why?
|
| HIV | 2 | 2023 | 189 | 0.170 |
Why?
|
| Inappropriate Prescribing | 1 | 2021 | 38 | 0.170 |
Why?
|
| Informed Consent | 1 | 2023 | 346 | 0.170 |
Why?
|
| Homosexuality, Male | 1 | 2020 | 72 | 0.170 |
Why?
|
| Ancylostomatoidea | 1 | 2020 | 60 | 0.170 |
Why?
|
| Anemia, Neonatal | 1 | 2020 | 8 | 0.160 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 32 | 0.160 |
Why?
|
| Phototherapy | 1 | 2020 | 39 | 0.160 |
Why?
|
| Skin | 1 | 2022 | 527 | 0.160 |
Why?
|
| Viral Load | 1 | 2021 | 408 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2020 | 68 | 0.160 |
Why?
|
| Anti-HIV Agents | 1 | 2023 | 348 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 270 | 0.150 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 138 | 0.150 |
Why?
|
| Health Education | 1 | 2020 | 235 | 0.150 |
Why?
|
| Sexual Behavior | 1 | 2020 | 250 | 0.150 |
Why?
|
| Hemoglobins | 1 | 2020 | 322 | 0.150 |
Why?
|
| Medication Adherence | 1 | 2021 | 326 | 0.140 |
Why?
|
| Public Health | 1 | 2020 | 281 | 0.140 |
Why?
|
| Decision Making | 1 | 2023 | 700 | 0.140 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3760 | 0.140 |
Why?
|
| Transition to Adult Care | 1 | 2019 | 118 | 0.140 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 946 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| HIV-1 | 1 | 2020 | 484 | 0.130 |
Why?
|
| Female | 8 | 2025 | 70664 | 0.130 |
Why?
|
| Pregnancy | 2 | 2020 | 7554 | 0.120 |
Why?
|
| Rural Population | 1 | 2017 | 239 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2023 | 17389 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 380 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 391 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2021 | 5168 | 0.110 |
Why?
|
| Adult | 4 | 2024 | 31571 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 569 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1185 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2017 | 793 | 0.090 |
Why?
|
| Rifampin | 2 | 2022 | 120 | 0.080 |
Why?
|
| United States | 2 | 2022 | 11660 | 0.080 |
Why?
|
| Male | 5 | 2025 | 64938 | 0.080 |
Why?
|
| Antitubercular Agents | 2 | 2022 | 264 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2025 | 6570 | 0.070 |
Why?
|
| Africa South of the Sahara | 1 | 2025 | 121 | 0.060 |
Why?
|
| Mozambique | 1 | 2024 | 22 | 0.050 |
Why?
|
| Tanzania | 1 | 2024 | 74 | 0.050 |
Why?
|
| Tuberculosis Vaccines | 1 | 2023 | 13 | 0.050 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 67 | 0.050 |
Why?
|
| False Negative Reactions | 1 | 2021 | 89 | 0.040 |
Why?
|
| Anti-Retroviral Agents | 1 | 2023 | 150 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2021 | 142 | 0.040 |
Why?
|
| Peru | 1 | 2020 | 56 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2021 | 277 | 0.040 |
Why?
|
| Bias | 1 | 2021 | 143 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2021 | 153 | 0.040 |
Why?
|
| Cough | 1 | 2021 | 96 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 42 | 0.040 |
Why?
|
| Reference Standards | 1 | 2021 | 242 | 0.040 |
Why?
|
| Sexual Partners | 1 | 2020 | 85 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 159 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 177 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 246 | 0.040 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2020 | 95 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 72 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 827 | 0.040 |
Why?
|
| Child Behavior | 1 | 2021 | 236 | 0.040 |
Why?
|
| Animals | 1 | 2020 | 34804 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2023 | 1457 | 0.040 |
Why?
|
| Fever | 1 | 2021 | 310 | 0.040 |
Why?
|
| Weight Gain | 1 | 2021 | 381 | 0.040 |
Why?
|
| Global Health | 1 | 2023 | 645 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 1018 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2025 | 3412 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2025 | 14734 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1572 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1478 | 0.030 |
Why?
|
| Comorbidity | 1 | 2020 | 1606 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 828 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2020 | 823 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2657 | 0.030 |
Why?
|
| Infant | 1 | 2025 | 13048 | 0.020 |
Why?
|
| Middle Aged | 1 | 2024 | 28993 | 0.010 |
Why?
|